Author

Mark Hoeprich

Kettering Medical Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Anthony Joseph Paravati· 1 shared Brett VanCauwenbergh· 1 shared Catherine A. BehrmanniD· 1 shared Daniel WooiD· 1 shared David R. PlasiD· 1 shared Eric Justin O'BrieniD· 1 shared Farah BarakatiD· 1 shared Hailey Spry· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anthony Joseph Paravati

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

CPI203, a BET inhibitor, down-regulates a consistent set of DNA synthesis genes across a wide array of glioblastoma lines.

Matthew C. Garrett, Troy Carnwath, Rebecca Albano, Yonghua Zhuang, Catherine A. Behrmann, Merissa Pemberton, Farah Barakat, Robert M. Lober, Mark Hoeprich, Anthony Joseph Paravati, Marilyn Reed, Hailey Spry, Daniel Woo, Eric Justin O'Brien, Brett VanCauwenbergh, , David R. Plas

This study identifies CPI203, a BET inhibitor, as a compound that consistently down-regulates DNA synthesis genes across multiple glioblastoma lines.

PLoS ONE · May 16, 2025Peer-reviewedCancer Biology